| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 1987* | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 444* | 2021 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 399 (10320), 143, 2022 | 233 | 2022 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 219 | 2022 |
| Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? A Hill, SL Hughes, D Gotham, AL Pozniak Journal of virus eradication 4 (2), 72-79, 2018 | 142 | 2018 |
| Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C A Hill, B Simmons, D Gotham, J Fortunak Journal of virus eradication 2 (1), 28-40, 2016 | 105 | 2016 |
| Estimated costs of production and potential prices for the WHO Essential Medicines List AM Hill, MJ Barber, D Gotham BMJ global health 3 (1), e000571, 2018 | 100 | 2018 |
| Production costs and potential prices for biosimilars of human insulin and insulin analogues D Gotham, MJ Barber, A Hill BMJ global health 3 (5), e000850, 2018 | 83 | 2018 |
| Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment A Hill, D Gotham, J Fortunak, J Meldrum, I Erbacher, M Martin, H Shoman, ... BMJ open 6 (1), e009586, 2016 | 69 | 2016 |
| Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications B Godman, A Hill, S Simoens, G Selke, I Selke Krulichová, ... Expert review of pharmacoeconomics & outcomes research 21 (4), 527-540, 2021 | 66 | 2021 |
| Reimbursement models to tackle market failures for antimicrobials: approaches taken in France, Germany, Sweden, the United Kingdom, and the United States D Gotham, L Moja, M van der Heijden, S Paulin, I Smith, P Beyer Health Policy 125 (3), 296-306, 2021 | 54 | 2021 |
| Pricing of oral generic cancer medicines in 25 European countries; findings and implications B Godman, A Hill, S Simoens, A Kurdi, J Gulbinovič, A Martin, A Timoney, ... Generics and Biosimilars Initiative Journal 8 (2), 49-70, 2019 | 51 | 2019 |
| Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis A Hill, C Redd, D Gotham, I Erbacher, J Meldrum, R Harada BMJ open 7 (1), e011965, 2017 | 46 | 2017 |
| Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries MJ Barber, D Gotham, G Khwairakpam, A Hill Journal of Virus Eradication 6 (3), 100001, 2020 | 45 | 2020 |
| Estimated generic prices for novel treatments for drug-resistant tuberculosis D Gotham, J Fortunak, A Pozniak, S Khoo, G Cooke, FE Nytko III, A Hill Journal of Antimicrobial Chemotherapy 72 (4), 1243-1252, 2017 | 44 | 2017 |
| Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials V Pilkington, SL Hughes, T Pepperrell, K McCann, D Gotham, AL Pozniak, ... Aids 34 (15), 2259-2268, 2020 | 43 | 2020 |
| Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide D Gotham, A Hill, AL Pozniak Current Opinion in HIV and AIDS 12 (4), 324-333, 2017 | 37 | 2017 |
| Analysis of minimum target prices for production of entecavir to treat hepatitis B in high-and low-income countries A Hill, D Gotham, G Cooke, S Bhagani, I Andrieux-Meyer, J Cohn, ... Journal of virus eradication 1 (2), 103-110, 2015 | 36 | 2015 |
| Patent pooling to increase access to essential medicines E Burrone, D Gotham, A Gray, K de Joncheere, N Magrini, YM Martei, ... Bulletin of the World Health Organization 97 (8), 575, 2019 | 34 | 2019 |
| How the MDGs gave up on measuring access to medicines D Gotham, KH Onarheim, MJ Barber The Lancet Global Health 4 (5), e296-e297, 2016 | 22 | 2016 |
Kristine H. OnarheimUniversity of BergenVerified email at uib.no
